KELOWNA, BC, July 13, 2020 /CNW/ - The Valens
Company Inc. (TSX: VLNS) (OTCQX: VLNCF) (the "Company"
or "The Valens Company"), a global leader in the
end-to-end development and manufacturing of innovative,
cannabinoid-based products, today announced its participation in a
Medical Cannabis Real-World Evidence Study (the "MC-RWE
Study") led by Dr. Hance Clarke of the University Health
Network (UHN) in Toronto, Canada.
The study will explore the therapeutic effects of medical cannabis
in adults with chronic pain, sleep, or anxiety issues, and will
leverage the blockchain secure technology of the Medical Cannabis
by Shoppers online product portal of both tested and verified
cannabis products.
The Valens Company has contributed to the study with the
inclusion of Nūance, its exclusive brand of premium cannabis
oil developed by the Company for Medical Cannabis by Shoppers. As
part of the study, the Nūance line of THC and CBD oils will be
tested, with the verified results on each batch made available
through the Medical Cannabis by Shoppers portal for each physician
and patient. Patients will be able to identify the contents of
their product through the platform, including potency levels of THC
and CBD, and confidently rely on the data to ensure batch-to-batch
consistency and quality. The goal of this study is to provide
physicians, pharmacists, and patients with confidence in medicinal
cannabis products as an alternate treatment for various ailments,
including pain relief.
"Nūance oils are developed exclusively for Shoppers Drug Mart
with medical cannabis patients at the core. To be able to
participate in this real-world study and have the opportunity to
understand how our products could be used as a treatment is an
exciting step in the right direction for us," said Tyler Robson, Chief Executive Officer of The
Valens Company. "With insights and data from this study, we look
forward to further advancing our commitment to developing and
testing the highest-quality and most reliable products for patients
using cannabis for both medical purposes as well as recreational
consumers."
"Medical Cannabis by Shoppers is best placed to offer Canadians
the reassurance of medical products that have been tested and
validated," said Ken Weisbrod, Vice
President, Business Development/Cannabis Strategy, Shoppers Drug
Mart. "Our development of a blockchain secured initiative with
TruTrace has now been integrated into an operational portal that
will provide products with an immutable digital identity that can
capture everything from detailed chemistry down to its DNA."
The MC-RWE Study is a prospective, non-interventional,
observational study to describe the benefits of medical cannabis
for various common medical issues and seeks to enroll at least
2,000 subjects from across Canada
who will be followed for 24 weeks. More on this study can be found
here.
About The Valens Company
The Valens Company is a global leader in the end-to-end
development and manufacturing of innovative, cannabinoid-based
products. The Valens Company is focused on being the partner of
choice for leading Canadian and international cannabis brands by
providing best-in-class, proprietary services including CO2,
ethanol, hydrocarbon, solvent-less and terpene extraction,
analytical testing, formulation and product development and custom
manufacturing. Valens is the largest third-party extraction
company in Canada with an annual
capacity of 425,000 kg of dried cannabis and hemp biomass at our
purpose-built facility in Kelowna,
British Columbia which is in the process of becoming
European Union (EU) Good Manufacturing Practices (GMP)
compliant. The Valens Company currently offers a wide range
of product formats, including tinctures, two-piece caps, soft gels,
oral sprays and vape pens as well as beverages, concentrates,
topicals, edibles, injectables, natural health products and has a
strong pipeline of next-generation products in development for
future release. Finally, The Valens Company's wholly-owned
subsidiary Valens Labs is a Health
Canada licensed ISO 17025 accredited cannabis testing lab providing
sector-leading analytical services and has partnered with Thermo
Fisher Scientific to develop a Centre of Excellence in Plant-Based
Science. For more information, please visit
http://thevalenscompany.com. The Valens Company's investor
deck can be found specifically at
http://thevalenscompany.com/investors/.
Notice regarding Forward Looking Statements
All information included in this press release, including any
information as to the future financial or operating performance and
other statements of The Valens Company that express management's
expectations or estimates of future performance, other than
statements of historical fact, constitute forward-looking
information or forward-looking statements within the meaning of
applicable securities laws and are based on expectations, estimates
and projections as of the date hereof. Forward-looking statements
are included for the purpose of providing information about
management's current expectations and plans relating to the future.
Wherever possible, words such as "plans", "expects", "scheduled",
"trends", "indications", "potential", "estimates", "predicts",
"anticipate", "to establish", "believe", "intend", "ability to", or
statements that certain actions, events or results "may", "could",
"would", "might", "will", or are "likely" to be taken, occur or be
achieved, or the negative of these words or other variations
thereof, have been used to identify such forward-looking
information. Specific forward-looking statements include, without
limitation, all disclosure regarding future results of operations,
economic conditions and anticipated courses of action.
The risks and uncertainties that may affect forward-looking
statements include, among others, regulatory risk,
United States border crossing and
travel bans, reliance on licenses, expansion of facilities,
competition, dependence on supply of cannabis and reliance on other
key inputs, dependence on senior management and key personnel,
general business risk and liability, regulation of the cannabis
industry, change in laws, regulations and guidelines, compliance
with laws, reliance on a single facility, limited operating
history, vulnerability to rising energy costs, unfavourable
publicity or consumer perception, product liability, risks related
to intellectual property, product recalls, difficulties with
forecasts, management of growth and litigation, many of which are
beyond the control of The Valens Company. For a more comprehensive
discussion of the risks faced by The Valens Company, and which may
cause the actual financial results, performance or achievements of
The Valens Company to be materially different from estimated future
results, performance or achievements expressed or implied by
forward-looking information or forward-looking statements, please
refer to The Valens Company's latest Annual Information Form filed
with Canadian securities regulatory authorities at
www.sedar.com or on The Valens Company's website at
www.thevalenscompany.com. The risks described in such Annual
Information Form are hereby incorporated by reference herein.
Although the forward-looking statements contained herein reflect
management's current beliefs and reasonable assumptions based upon
information available to management as of the date hereof, The
Valens Company cannot be certain that actual results will be
consistent with such forward-looking information. The Valens
Company cautions you not to place undue reliance upon any such
forward-looking statements. The Valens Company disclaims any
intention or obligation to update or revise any forward-looking
statements whether as a result of new information, future events or
otherwise, except as required by applicable law. Nothing herein
should be construed as either an offer to sell or a solicitation to
buy or sell securities of The Valens Company.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/the-valens-company-announces-participation-in-first-of-its-kind-real-world-evidence-study-on-medical-cannabis-led-by-the-university-health-network-in-partnership-with-shoppers-drug-mart-301091996.html
SOURCE The Valens Company Inc.